AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Bruce Japsen, Chicago Tribune
Dec. 21--By the end of the decade, consumers should have another prescription-strength option to treating heartburn that won't burn a hole in their wallets.
TAP Pharmaceutical Products Inc. has agreed to license rights to its blockbuster heartburn drug Prevacid to health-care giant Novartis AG, which plans to launch an over-the-counter pill once the patent on TAP's prescription version expires in 2009.
That is expected to be good news for millions of heartburn sufferers who may be looking for a cheaper and similarly effective option to expensive brand-name drugs like prescription-strength Prevacid and Nexium, which cost about $4 a pill on average at retail. An over-the-counter version is expected to ...